Preclinical studies have demonstrated the potential of miRNA-based therapies in ovarian cancer, such as the use of an miR-34a mimic, which induces apoptosis and inhibits cell proliferation, migration, and invasion by targeting multiple oncogenic pathways, including Notch, Wnt, and PI3K/AKT [56]. Here, AKT1 is linked to ovarian carcinoma.